Sign in
JANX Stock Price, Chart, Stats & News
Janux Therapeutics, Inc.
Save
Janux Therapeutics, Inc. (JANX) does not currently pay a dividend.
1.05B
Market cap
–
Current P/E
–
Forward P/E
JANX chart
Fundamentals
Gross margin | 47.20% |
Operating margin | -881.81% |
Pretax margin | -635.49% |
Net margin | -635.49% |
Effective tax rate | – |
ROA | -11.34% |
ROE | -11.55% |
D/E | 0.04x |
Interest coverage ratio | – |
JANX valuation
P/E | – |
P/S | 44.84x |
P/B | 0.85x |
P/CF | – |
P/FCF | – |
P/OCF | – |
PEG | 0.81x |
EV multiple | -6.05x |
About
Janux Therapeutics, Inc. is a biopharmaceutical company dedicated to developing innovative cancer therapies. The firm leverages its proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to create treatments designed to activate the body's T cells to fight tumors. Currently, Janux has several promising TRACTr product candidates in their early preclinical or discovery stages, which are engineered to target specific antigens such as prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2.
Similar securities
Based on sector and market capitalization
Report issue